No Picture
News

Respivant Sciences Announces Dosing of First Patient in Phase 2b Trial of RVT-1601 for the Treatment of Persistent Cough Due to Idiopathic Pulmonary Fibrosis

RVT-1601 previously demonstrated a statistically significant and clinically meaningful reduction in IPF-related cough in a Phase 2a studyRespivant also launches new website – IPFCough.com – as educational resource for patients and to increase awareness… […]

No Picture
News

Reneo Pharmaceuticals Raises $50 Million to Develop Therapeutics to Treat Genetic Mitochondrial Diseases

SAN DIEGO, May 20, 2019 /PRNewswire/ — Reneo Pharmaceuticals, a clinical stage pharmaceutical company, today announced that it has completed a $50 million Series A financing to develop therapies for diseases associated with deficits in cellular met… […]

No Picture
News

ACADIA Pharmaceuticals to Present Phase 2 CLARITY Results for Pimavanserin as an Adjunctive Treatment in Major Depressive Disorder at the 2019 American Psychiatric Association Annual Meeting

SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today annou… […]

No Picture
News

Microbiota Restoration Takes the Podium at DDW 2019: Investigational Microbiota-Based Therapies for Recurrent C. diff Highlighted

ROSEVILLE, Minn.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/Cdiff?src=hash" target="_blank"gt;#Cdifflt;/agt;–Rebiotix to present research data on current microbiome trials at DDW 2019 in San Diego, CA (May 18-21). […]